Sorvate-C

Quick links to important sections

Sorvate-C

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sorvate-C

What is Sorvate-C and What Type of Medicine is It?

Sorvate-C is a prescription medicine intended exclusively for topical use on the skin. It is structurally classified as a combination product because it contains two distinct active ingredients that belong to separate pharmacological classes. This preparation is primarily available as an ointment, but may also be found in other topical forms such as a cream, solution, or foam. The combination of a super potent corticosteroid and a Vitamin D analogue is its definitive structural feature, providing a comprehensive approach to managing chronic skin disorders.

Composition: Calcitriol and Clobetasol Propionate

The formulation's core is the pairing of Clobetasol Propionate and Calcitriol, both of which are synthetic compounds utilized for their distinct actions on the skin. Clobetasol Propionate is a highly potent corticosteroid, which establishes the rapid and strong anti-inflammatory property of the component. Calcitriol is the chemically synthesized equivalent of the body's natural active metabolite of Vitamin D3, and is classified as a Vitamin D analogue. The combination is designed for adult patient groups experiencing chronic skin conditions.

General Purpose and Dual Mechanism of Effect

The general purpose of combining these agents is to produce a synergistic effect, allowing the drug to simultaneously manage both the symptoms of inflammation and the underlying disorder of skin cell growth. The Clobetasol Propionate component provides strong anti-inflammatory action by suppressing the localized immune reaction. The Calcitriol component complements this action by working to modulate the abnormal proliferation (overgrowth) of skin cells, thus addressing core symptoms such as redness, intense itching, and scaling. This dual mechanism is utilized in scenarios characterized by both inflammatory discomfort and rapid cell turnover.

What side effects are possible with Sorvate-C?

Possible Side Effects and Safety Information

The official safety profile for the topical combination of Calcitriol and Clobetasol Propionate outlines both local skin reactions and potential systemic effects linked to regulatory classifications.

Key Adverse Reaction Categories

Adverse reactions are classified by frequency as documented in regulatory sources:

  • Common: Reactions frequently observed include skin atrophy (thinning), striae (stretch marks), telangiectasia, and a burning sensation or pain at the application site.
  • Uncommon: Less frequent effects include folliculitis, allergic contact dermatitis, and changes in skin pigmentation (hypopigmentation).
  • Rare / Frequency Not Known: These include serious systemic reactions due to absorption, such as Adrenal Suppression (HPA axis suppression), Cushing's Syndrome, and Hypercalcemia.

Systemic and Application Constraints

The safety documentation identifies risks related to the potent components:

System-Organ Class Specific Safety Concern
Endocrine/Metabolism Potential for Adrenal Suppression or Hypercalcemia (systemic absorption)
Eye Disorders Documented risk of glaucoma or cataracts (when applied near the eye)

Exposure- and Population-Specific Notes

The official labeling notes that effects like skin atrophy and the risk of systemic effects are more strongly associated with prolonged use. Conversely, local sensations like burning are often reported as more common at the start of treatment. Regulatory texts highlight that the pediatric population is at a greater risk of systemic toxicity compared to adults due to increased absorption rates.

The official safety documentation emphasizes that the risk of systemic effects increases with application to large areas, under occlusion, or in skin folds, defining critical safety constraints for use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Sorvate-C overdose reflects the distinct systemic risks of its two components following excessive topical application.

Corticosteroid Component Risks

Overabsorption of the Clobetasol Propionate component may result in documented manifestations of reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. Clinical signs of systemic toxicity may include Cushing’s syndrome, hyperglycemia, and glucosuria. Pediatric patients and individuals with liver impairment are noted as having increased susceptibility to these systemic effects.

Vitamin D Analogue Component Risks

Overexposure to Calcitriol is officially linked to progressive hypercalcemia, hypercalciuria, and hyperphosphatemia. Severe, life-threatening outcomes from chronic uncorrected hypercalcemia can involve generalized vascular calcification and nephrocalcinosis.

Regulatory-Mandated Emergency Actions

Immediate medical attention must be sought for cases involving severe progressive hypercalcemia. If hypercalcemia is detected, the regulation requires the immediate discontinuation of the drug. Management of overdose is defined as symptomatic and supportive treatment, with no specific antidote officially documented. Periodic monitoring, including HPA axis testing and serum calcium level checks, is a required clinical procedure.

Therapeutic Uses of Sorvate-C

What Sorvate-C Treats: Main Uses and Benefits

The combination is commonly used for managing specific chronic inflammatory skin conditions, used in situations involving both symptomatic discomfort and related structural manifestations of the condition.

This treatment is considered relevant for chronic plaque psoriasis, which is characterized by persistent, thick, raised patches of skin. It is commonly applied in contexts where the disease is classified as moderate-to-severe, supporting the management of chronic lesions and their associated symptoms. The approach may assist in addressing conditions that involve inflammatory or irritative processes that become more disruptive during flare-ups, such as intense redness (erythema), persistent pruritus (itching), and excessive scaling.

The medication supports the easing of symptoms related to inflammatory states, contributing to supportive relief from associated distressing symptoms. By supporting the management of skin cell production, it helps address the structural manifestations of the condition. This symptomatic relief may assist with improving day-to-day comfort during symptomatic periods. The active components are commonly used to help with the relief of these manifestations.

“The primary goal is to help patients cope more steadily with symptom fluctuations and support general well-being during symptomatic phases.”


Quick Fact: Relief for Intense Itching
The medication assists with maintaining functional stability by easing pruritus and irritation, which are common symptoms that interfere with daily comfort during flare-ups.

Regulatory References

  1. NIH DailyMed Label

Eligibility and Restrictions for Use

The official eligibility profile for Sorvate-C, a Clobetasol Propionate/Calcitriol combination, is defined by regulatory documents based on the components' potential for systemic effects and specific contraindications.

Contraindicated Populations

The medicine is contraindicated and must not be used in patients with a known hypersensitivity to any component. It is also prohibited for use in patients with rosacea, perioral dermatitis, acne vulgaris, or primary viral, fungal, or tubercular infections at the treatment site.

Eligibility and Restrictions

Category Official Regulatory Status
Eligible Age Group Approved for adults and adolescents 12 years of age and older (in line with specific component formulations).
Pediatric Use Use is not recommended in children under 12 years of age, as safety and efficacy have not been established.
Pregnancy/Lactation Use should be avoided unless clearly necessary due to systemic risk. Application on the nipple/breast area must be avoided during lactation.
Condition Restrictions Use requires special caution in patients with severe liver or renal impairment or Diabetes Mellitus.
Application Limits Must not be applied to the face, groin, or axillae (underarms) or on broken skin or skin atrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Sorvate-C addresses potential interactions based on the distinct pharmacological properties of its two active components: a potent corticosteroid and a Vitamin D analogue. These interactions are categorized based on their impact on drug metabolism and systemic calcium balance.

Interaction Classification Interacting Agents or Conditions
Metabolic Pathway Competition Ritonavir, Itraconazole, and other potent CYP3A4 inhibitors.
Calcium Balance Interference Systemic Vitamin D analogues, Calcium Supplements, Thiazide Diuretics.
Systemic Exposure Modifiers Occlusive dressings, Application to large surface areas.

Official Interaction Statements

The Clobetasol Propionate component is a substrate for the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors, such as the medicines Ritonavir and Itraconazole, is documented to cause a pharmacokinetic interaction. This inhibition of metabolism may lead to increased systemic exposure of the corticosteroid component.

For the Calcitriol component, the interaction profile notes agents that affect calcium. Co-administration with products that increase serum calcium concentrations, including systemic Vitamin D analogues, calcium supplements, and Thiazide Diuretics, carries an additive risk of hypercalcemia.

The regulatory documentation formally restricts certain application methods: the use of occlusive dressings or application to large areas of the body is noted to increase the percutaneous absorption of both active ingredients. This procedural constraint modifies the risk profile by potentially increasing overall systemic exposure.

Mechanism of Action

Sorvate-C is a combination topical agent containing betamethasone dipropionate, a corticosteroid, and calcipotriene, a vitamin D analog. The mechanism of action involves the simultaneous influence of these two molecules on distinct intracellular pathways governing epidermal cell function and localized inflammation.

Calcipotriene acts as an agonist for the Vitamin D Receptor (VDR), a nuclear receptor. VDR activation modulates the transcription of specific genes responsible for controlling keratinocyte proliferation and differentiation, resulting in a decreased epidermal cell turnover rate.

Betamethasone dipropionate acts by binding to the cytoplasmic Glucocorticoid Receptor (GR). The activated GR complex translocates to the nucleus where it alters gene expression, decreasing the transcription of genes that encode pro-inflammatory mediators, such as cytokines and chemokines. This action modulates the local inflammatory cascade.

Together, these two mechanisms influence cellular signaling pathways that govern epidermal growth and modulate factors driving hyperproliferation.

Dosage and Administration Information

How to Use Sorvate-C: Official Administration Guidelines

Sorvate-C is a prescription medicine formulated exclusively for topical dermatologic use, applied directly to the skin. Usage instructions are established to ensure precise control over the highly potent corticosteroid component.


Application Dosing and Frequency

The medication must be applied as a thin layer to the affected skin areas twice daily (BID), typically once in the morning and once in the evening. The total dosage applied must not exceed 50 grams (50 g) per week.

Duration and Procedural Constraints

Treatment with Sorvate-C is strictly time-limited and should not exceed a maximum of two consecutive weeks. Application must be discontinued immediately when control is achieved, defining a critical endpoint for therapy. The product is not recommended for patients under 12 years of age.

Official Procedural Structure:

  • Apply a thin layer to the affected skin.
  • Gently rub the medicine into the skin.
  • Repeat the application twice daily.
  • Do not cover the treated area with any dressing.
  • Avoid applying to the face, groin, or axillae.
  • Wash hands thoroughly after the application.

These requirements define the protocol for using Sorvate-C as a highly restricted, short-term topical regimen, governing the frequency and total dosage to limit exposure.

Recent Clinical Evidence

Sorvate-C: Recent Clinical Evidence

Evidence for Use in Chronic Plaque Psoriasis

Research for the combination product was primarily conducted in short-term, randomized controlled trials (RCTs) involving adults diagnosed with chronic plaque psoriasis. These studies explored clinical outcomes such as the Physician/Investigator Global Assessment (PGA/IGA) and the Psoriasis Area and Severity Index (PASI), which measure how symptoms change over time. Studies reported measurements showing that a higher proportion of participants using the combination product achieved a "Clear" or "Almost Clear" status on the PGA/IGA scale when compared with assessment scores from the vehicle group. Research also examined changes across specific symptoms, including redness, scaling, and itching.

Comparative Evidence and Study Duration

The combination product was evaluated in studies comparing it directly against its two monotherapy components: Calcitriol and Clobetasol Propionate alone. Findings indicate patterns related to the clinical assessment scores measured over defined time intervals when compared to each active component. Limited comparative evidence is lacking in trials that included direct evaluation against certain other therapeutic options.

The core clinical evidence was derived from studies conducted over short treatment periods, typically ranging from 2 to 4 weeks. It is not yet clear whether the outcomes related to systemic or functional imbalance are well-established over longer timeframes. Long-term patterns were not fully captured by the available study designs, as longer-duration research often involved sequential or rotational therapy regimens for maintenance.

Evidence in Specific Patient Populations and Uncertainties

Research focused predominantly on a specific population: adults with chronic plaque psoriasis. Data for certain groups remain insufficient, including limited data available for pediatric patients or populations with significant comorbid conditions. A primary focus of uncertainty relates to long-term outcomes, as the small sample sizes in some studies were noted as a factor that may influence the generalizability of the findings.

Key Studies & References Label: CLOBETASOL PROPIONATE cream (DailyMed/FDA Label)

Frequently Asked Questions (FAQ)

Common questions about Sorvate-C (FAQ)

Q: Does Sorvate-C cause hair loss?

Hair loss, or alopecia, has been reported in post-marketing surveillance for Clobetasol Propionate, which is one of the active ingredients in Sorvate-C. This is not typically listed as a common reaction in clinical trials, and the frequency of its occurrence is not always known in the official safety documentation.

Q: Are there any specific foods to avoid when using Sorvate-C?

Official guidance from drug authorities indicates that patients can generally eat and drink normally while using this medicine.

However, because the product contains a Vitamin D analogue, it is necessary to be aware that systemic Vitamin D supplements or calcium supplements are listed as interacting agents that affect calcium balance.

Q: How long until I might see or feel the effects of Sorvate-C?

Studies and official information suggest that improvement in the affected skin condition is generally observed during the first two weeks of treatment. If symptoms do not improve during this time frame, consulting a healthcare provider is generally recommended.

Q: What happens if I miss a dose of Sorvate-C?

If a dose of Sorvate-C is missed, the official regulatory instructions recommend applying it as soon as it is remembered. However, if it is nearly time for the next scheduled application, the missed dose should be skipped.

Official regulatory instructions advise against applying a double dose to compensate for a missed one.

Q: Is Sorvate-C considered a steroid or a biologic?

Sorvate-C is a combination product that contains a synthetic, super-high potency topical corticosteroid and a synthetic Vitamin D analogue. It is officially classified by regulatory bodies based on these two pharmacological classes, and it is not considered a biologic medicine.

Q: Does using Sorvate-C affect my ability to drive?

The active components of Sorvate-C are not known to directly affect the ability to drive or operate machinery. If rare systemic side effects occur that lead to dizziness or severe tiredness, the ability to drive or operate machinery may be affected.

Q: Can Sorvate-C make you feel tired or dizzy?

Unusual tiredness or dizziness are not typically listed as common side effects of Sorvate-C. These symptoms have been reported in connection with rare systemic effects of potent topical steroids, which can sometimes affect the body's hormone balance.

Q: Is it safe to drink alcohol while on Sorvate-C?

Official regulatory guidance regarding the Calcipotriene component confirms that drinking alcohol is generally acceptable while using the medicine. Alcohol is not listed as a known interacting agent for either active component in the product's official safety profile.

Q: How is Sorvate-C different from over-the-counter creams?

Sorvate-C is a prescription-only medicine because one of its active components, Clobetasol Propionate, is classified as a super-high potency topical corticosteroid. Over-the-counter (OTC) creams do not contain ingredients of this high potency, making Sorvate-C a highly restricted treatment requiring professional oversight.

Q: Will Sorvate-C cure my condition, or just manage the symptoms?

Official regulatory documents state that the medicine is indicated for the relief of symptoms, specifically the inflammatory and itchy manifestations of certain chronic skin conditions.

The medicine is intended for the temporary control and management of symptoms associated with chronic conditions, which are not known to be cured by topical agents.

Q: What is the risk of addiction or dependence with Sorvate-C?

Long-term, continuous use of potent topical steroids can lead to a reaction known as Topical Steroid Withdrawal (TSW) upon cessation, which results in severe skin symptoms. This adverse reaction pattern is a recognized risk associated with the corticosteroid's potency. It is important to note that this reaction pattern is generally not classified as classical addiction or physical drug dependence in the same way as other substance use disorders.

Q: What should I do if my condition gets worse after starting Sorvate-C?

Regulatory guidance indicates that patients should seek the advice of their healthcare provider right away if their skin condition worsens or persists after starting treatment with Sorvate-C.

If an infection is present or develops in the area, it may be necessary to discontinue the use of Sorvate-C until the infection is adequately controlled.

Q: Is there a generic version of Sorvate-C available?

The Clobetasol Propionate component of Sorvate-C is widely available as a generic medication in various topical forms. The specific combination product may have generic availability depending on the regulatory status and specific formulation in a given market.

Q: Does Sorvate-C increase sensitivity to the sun?

Studies and official information indicate that the Calcipotriene component can make the skin more sensitive to sunlight. Patients may need to discuss appropriate sun protection measures with their healthcare provider.

Q: Is it required to have a specific diagnosis before using Sorvate-C?

As a prescription-only medicine containing highly potent ingredients, Sorvate-C is indicated for the treatment of specific, confirmed skin conditions, such as moderate to severe plaque psoriasis.

A healthcare professional's diagnosis is required to confirm eligibility for its use.

Q: How is the safety of Sorvate-C monitored after it has been approved?

The safety of approved drugs like Sorvate-C is continuously monitored after approval through post-marketing surveillance programs, such as the FDA MedWatch program.

The mechanism exists for side effects to be reported to these regulatory systems to contribute to the ongoing safety assessment.

Q: Is there a warning about using Sorvate-C with herbal products?

Regulatory documents advise patients to inform their healthcare provider of all products they are currently taking or plan to take. This includes prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products, as their use may introduce unforeseen interactions.

Q: What is the official classification of Sorvate-C (e.g., immunosuppressant, anti-inflammatory)?

Sorvate-C is officially classified as a combination product. The Clobetasol Propionate component is recognized for its anti-inflammatory and immunosuppressive effects, while Calcipotriene is a synthetic Vitamin D analogue.

Q: Why do some people stop using Sorvate-C?

Official instructions require that treatment be discontinued immediately once control over the condition is achieved, as the therapy is strictly time-limited.

Patients may also stop if they experience unacceptable local adverse reactions like severe irritation, or if a skin infection is not controlled, requiring them to consult their healthcare provider.

Q: Does Sorvate-C affect mood or cause anxiety?

Changes in mood, such as depression, irritability, or confusion, are not common side effects. However, official safety profiles have reported these as symptoms related to the rare systemic effects of potent topical steroids, which can sometimes affect the body's hormone balance.

Q: Can I stop using Sorvate-C suddenly, or do I need to taper off?

The official protocol states to discontinue use when control is achieved. However, if the medicine has been used for an extended period, official information indicates that a gradual reduction (tapering) may be necessary.

This measure is taken to minimize the risk of a severe Topical Steroid Withdrawal reaction upon stopping.

Q: Can I use other topical products while using Sorvate-C?

If patients use other non-medicated topical products, such as moisturizers, official guidance recommends separating the applications by approximately 30 minutes. This helps ensure that each product is properly absorbed without reducing the effectiveness of Sorvate-C.

Q: Does Sorvate-C have any official Boxed Warnings or similar safety alerts?

The official FDA label contains warnings regarding the potential for serious systemic risks, including Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the risk of Cushing’s Syndrome.

These warnings highlight the most serious safety constraints associated with using a super-high potency steroid.

Q: Are there any required tests or check-ups while using Sorvate-C?

For patients applying the potent steroid to large areas, periodic evaluation for evidence of HPA axis suppression may be necessary. This evaluation can involve specific blood or urine tests, such as the ACTH stimulation test, the A.M. plasma cortisol test, or the urinary free cortisol test.

Q: Can Sorvate-C be used by people with compromised immune systems?

The Clobetasol Propionate component is a corticosteroid recognized for its immunosuppressive effects. Therefore, discussion with a healthcare professional regarding the use of Sorvate-C is important if a patient has a compromised immune system or a concomitant infection.

Q: Where can I find the official patient information leaflet for Sorvate-C?

The official patient information, often called a Patient Information Insert or Patient Information Leaflet, is supplied with the medicine.

This official regulatory document is typically provided to the patient by the dispenser at the time the prescription is filled.

How should Sorvate-C be stored and disposed of?

How to Store and Dispose of Sorvate-C

The storage and disposal of Sorvate-C (Calcitriol/Clobetasol Propionate) must strictly adhere to regulatory labeling to maintain product stability and ensure safety.


Storage Requirements

  • Temperature: Store at Controlled Room Temperature (20°C to 25°C / 68°F to 77°F).
  • Prohibited Environments: Do not refrigerate or freeze. Protect from excessive heat.
  • Container: Keep the container tightly closed. The foam formulation is flammable and must be kept away from open flame.
  • Child Safety: Keep the medicine out of the sight and reach of children.

Disposal Instructions

  • Unused or expired product must be disposed of according to local regulations.
  • Do not dispose of via household wastewater or sewage to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sorvate-C found in:

A-Z Index: